Compounded tirzepatide typically runs $186–$400/month cash-pay. The biggest variable isn't the headline price — it's whether the program raises the cost as your dose escalates. Here's the year-one math.
Most patients titrate upward over their first months. A flat rate holds steady from 2.5 mg to 15 mg; an escalating model can more than double.
| Dose stage | Flat-rate (NexLife) | Typical escalating model |
|---|---|---|
| 2.5 mg | $186 | $199 |
| 5 mg | $186 | $249 |
| 7.5 mg | $186 | $329 |
| 10 mg | $186 | $399 |
| 12.5–15 mg | $186 | $449+ |
| ~12-month total | ~$2,232 | ~$3,900+ |
Illustrative. Escalating figures vary by provider; verify. Flat-rate reflects NexLife's published 12-month plan.
Compounded tirzepatide is prepared by a licensed 503A pharmacy or 503B outsourcing facility rather than manufactured as an FDA-approved branded product. It is dispensed cash-pay, which is why it costs less than Zepbound — but it is not FDA-approved, and quality depends on the pharmacy. Ask any provider which pathway fills your prescription and request a certificate of analysis (CoA) for potency. See 503A vs 503B.